Skip to articles

The Aperture Science journal

RSS feed

Cardiology Insights.

Research in context.
Perspectives for South African clinical teams.

Explore our cardiology portfolio

From the journal

6 articles

Structural Heart

PASCAL enters US tricuspid repair—before the pivotal data arrive

US approval expands the tricuspid TEER conversation, while unpublished randomised outcomes keep comparative claims and South African assumptions off limits.

US FDA approval announced · pivotal randomised outcomes not yet public · no comparative superiority claim

Aperture Science Clinical Team

Week ending 5 min read
Structural Heart

Four lots, one safety signal: the Commander M FDA alert

Four delivery-system lots, one urgent safety question: translating the FDA’s Commander M alert into precise checks without overstating its scope.

FDA early safety alert · lot-specific action · no comparative risk estimate

Aperture Science Clinical Team

Week ending 5 min read
Interventional Cardiology

STORM-PE: walking recovery after pulmonary embolism

STORM-PE’s 90-day results link thrombectomy with better walking performance, while incomplete follow-up and limited safety power warrant careful clinical interpretation.

Randomised trial · secondary 90-day outcomes · abstract-based appraisal

Aperture Science Clinical Team

Week ending 5 min read
Interventional Cardiology

A sirolimus balloon for coronary ISR: what the US approval means

FDA approval of a sirolimus drug-eluting balloon for coronary restenosis expands options, but trial nuances still matter for careful adoption.

US regulatory announcement · randomised non-inferiority trial

Aperture Science Clinical Team

Week ending 5 min read
Devices & Technology

More heart data, not a diagnosis: what Apple Watch Series 12 changes

Apple Watch Series 12 samples heart data more frequently. We examine clinical implications, evidence limits and South African workflow questions.

Manufacturer launch · evidence-context review

Aperture Science Clinical Team

Week ending 5 min read